These mutations rarely exist (0–3%) in primary tumors [11, 15, 17, 24, 25] but are relatively common in metastatic endocrine therapy-resistant breast cancer lesions, with a wide-ranging prevalence of 6–55% [10,11,12,13, 15, 17,18,19,20,21,22,23,24,25, 27, 29]. The ...
Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients' health‐related quality of life (HRQOL) and treatment outcomes...
Breast cancers are phenotypically and genotypically heterogeneous tumors containing multiple cancer cell populations with various metastatic potential. Aggressive tumor cell subpopulations might more easily be captured in lymph nodes metastases (LNM) than in primary tumors (PT). We evaluated mRNA and protei...
14. Soares LR, Rosa VDL, Freitas-Junior R, Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: Bridging the gap between clinical trials and real life: Breast Cancer Res Treat, 2020; 181(3); 693-94 15. The World bank: World Bank Blogs Available from:https...
News | Prostate Cancer Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...
[63,71,72]. Interestingly, breast and lung cancer cell lines that were derived from bone marrow aspirates also expressed αvβ3, suggesting that it plays a role in overall metastasis of cancer cells to bone marrow [70]. PCa cell adhesion to and migration on components present in the bone...
Updated Phase III Data confirms the role of eribulin (Halaven™ also E7389, Eisai Inc) as a potential new standard of care for women with heavily pretreated metastatic breast cancer (MBC). The trial data was published in The Lancet earlier today. The EMBRACE trial (J Cortes...
Al-Hajj M, Wicha MS, Benito-Hernandez A: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100. Article CAS PubMed PubMed Central Google Scholar Collins AT, Berry PA, Hyde C: Prospective identification of tumorig...